TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Reduction in shoulder and back pain duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Depression improvement measured by HAM-D
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Depression improvement measured by MADRS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Decrease in psychomotor retardation measured by Widlocher Psychomotor Retardation Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CPSI score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: maximum flow rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: maximum urethral pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Erection duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ejaculation induction success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Semen motility rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMI standard deviation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child handling the visit better
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improving the child's ability to cope
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Aerobic performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptance regarding breathing
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Acceptance regarding communication
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: proportion of patients with concentric LVH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: proportion of patients with normal LV mass or geometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Isotonic strength increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biopsy-proven acute rejection episodes (BPAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Decrease of T level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Median total Brief Psychiatric Rating Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects rated as improved globally
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 5-year glycated hemoglobin (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 5-year triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cognition improvement trend
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: escitalopram serum concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nortriptyline serum concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infarct wall movement velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of recovery from recurrent ischemic stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plaque formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: microflora in plaque and saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fluoride retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of presyncope or syncope events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delayed off-site syncopal-type reactions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tiredness after donation
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: mean skin shrinkage ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: mean skin stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement in Ishak fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Safety and tolerability of HIVIGLOB infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Goal attainment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Failure at tendon-suture interface
Endpoint domain: Adverse events/effects
Primary endpoint: self-reported knee pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year mortality risk estimation
Endpoint domain: Mortality/survival
Primary endpoint: Patients' D-Option scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Physicians' D-Option scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient-reported assumed roles
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Elimination clearance of propofol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distribution clearance of propofol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral volume of distribution of propofol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Significant progression of cataractous eyes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in SSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quadriceps muscle activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Elvitegravir pharmacokinetic GMR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: etravirine AUC(tau)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ritonavir AUC(tau)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proficiency examination pass rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of BNIs performed per EP
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean duration of BNI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically significant relapse of depression
Endpoint domain: Adverse events/effects
Primary endpoint: increase in brain activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: intraindividual gait variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbiological cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of cognitive functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: decreasing gambling behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Superior maximum thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inferior maximum thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in urinary incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in bowel incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body weight change at day +28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum protein concentrations at discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative nitrogen balance at day +9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Behavioral response to MPH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infusion reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Grade 2 or 3 proteinuria
Endpoint domain: Adverse events/effects
Primary endpoint: IIEF-5 score
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Adherence to antiretroviral treatment (100% of pills taken)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stage distribution improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interobserver misclassification rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibody response to tetanus toxoid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage achieving >1 microg/ml antibody against specific pneumococcal serotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Distress from nausea
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in BCVA of 10 or more letters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in visual quality-of-life scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: chest pain exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: odynophagia exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: dysphagia exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Immediate and delayed recall performance with semantic processing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: peri-implant bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: maximum pronation during the stance phase of gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical and behavioral manifestations of PMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite lifestyle risk factor score for Alzheimer’s disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WTW distance and ACD measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CAMCOG‐R global score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: TMT A performance time
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: RAVLT summation score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Duration of induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained viral response (SVR) rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postexercise proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: postexercise albuminuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: postexercise renal clearance of albumin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Knowledge of breast reconstruction
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Confidence in understanding reconstruction information
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in neglected symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability in neurological function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: wound burst pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating ALA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to all-cause discontinuation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: COPD-related dyspnea on exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of opiate-negative urine tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Employment function (ASI employment scores)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Stress level (PSS total score)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Attrition rates
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Recurrence of iron deficiency (ID)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for once-monthly ibandronate over once-weekly alendronate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ease of following a treatment regimen for a long time
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Convenience of once-monthly ibandronate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: tolerance of nasal tube passage and laryngeal tube advancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hemodynamic response suppression to nasal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recall of the procedure
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean score of breast fissures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Adverse reactions (ADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: FG level reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 2 h PG level reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Heart Failure hospitalizations
Endpoint domain: Mortality/survival
Primary endpoint: IFN‐γ/IL‐2 ratio after polyclonal stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IL‐17A/IL‐2 ratio after polyclonal stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: TT‐specific IL17‐A response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: overall success rate after primary EN-DCR
Endpoint domain: Mortality/survival
Primary endpoint: Early recovery from anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perception of pain after surgery
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: rectal whole-crypt LI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: cytolytic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma clearance of ketamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ketamine : norketamine plasma metabolic ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of ketamine adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: bronchodilatation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: biomarkers of cardiovascular risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cumulative probability of developing clinically definite multiple sclerosis
Endpoint domain: Mortality/survival
Primary endpoint: Volume and number of T2-weighted lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Volume of gadolinium-enhancing lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement in NCI‐CTCAE sensory neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement in PNQ scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WOMAC pain decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical function increase
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Participants achieving post-primary vaccination anti-PRP levels ≥1µg/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: school absences
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Identification of patients with intestinal metaplasia (IM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ease of use of insulin pen
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Confidence in correct and complete insulin delivery
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Preference for FT over KP
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Tracking of physical activity and inactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best-spectacle corrected high contrast visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attrition of mother-infant pairs at 6 months postpartum
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of mothers retained and virally suppressed at 6 months postpartum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Children experiencing sunburn
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Clinical improvements in PD, CAL, and BOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in counts of A. actinomycetemcomitans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in counts of P. gingivalis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse ocular symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Cycloplegic effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Proportion of embryos reaching the morula stage after day 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of cells at the blastocyst stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inner cell mass:trophectoderm ratio at the blastocyst stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean absolute relative difference (MARD) during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lag in CGM during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: duration of throat-related symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of adverse effects (nausea and diarrhoea)
Endpoint domain: Adverse events/effects
Primary endpoint: Early response rate
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: proportion of participants self-monitoring blood glucose
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence of lupin allergy in peanut-allergic children
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitization to lupin in atopic controls
Endpoint domain: Adverse events/effects
Primary endpoint: grade 2 chronic xerostomia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee flexion moments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee valgus moment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: successful treatments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment retention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: social support for pregnant partners
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Reduction of clinician-rated ADHD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean difference of VAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean difference of total WOMAC score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to complete sensory block regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Home discharge time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioequivalence of tibolone doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Net savings per nurse
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Fugl‐Meyer score increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke Impact Scale recovery subscale increase
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning